{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:42:20Z","timestamp":1761100940108},"reference-count":43,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,3,3]],"date-time":"2008-03-03T00:00:00Z","timestamp":1204502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The role of haematopoietic stem cell transplantation (HSCT) in relapsed follicular lymphoma remains controversial. This study analysed 126 patients with relapsed, advanced stage follicular lymphoma who received BEAM (BCNU [carmustine], cytarabine, etoposide, melphalan)\u2010alemtuzumab allogeneic HSCT (BEAM\u2010allo) (<jats:italic>n<\/jats:italic>\u2003=\u200344) or BEAM\u2010autologous HSCT (BEAM\u2010auto) (<jats:italic>n<\/jats:italic>\u2003=\u200382). The BEAM\u2010allo group had a younger median age (48\u2003years vs. 56\u2003years, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b7001) but received a higher median number of therapies pretransplant (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7015) compared with the BEAM\u2010auto group. There was a higher non\u2010relapse mortality (NRM) in the BEAM\u2010allo group compared with the BEAM\u2010auto group at 1\u2003year (20% vs. 2%, <jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7001). Older age and heavily pretreated patients were associated with a higher NRM and poorer survival in the BEAM\u2010allo group. There was, however, a significantly lower relapse rate (20% vs. 43%, <jats:italic>P<\/jats:italic>\u2003=\u20030\u00b701) at 3\u2003years with BEAM\u2010alemtuzumab, with no relapses after 2\u2003years, compared with a continued pattern of relapse in the autologous group. No difference in overall survival (OS) (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b799) or disease\u2010free survival (DFS) (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b790) was identified at 3\u2003years, whereas a plateau in OS and DFS with crossing of the survival curves in favour of BEAM\u2010allo group was observed. Furthermore, the ability to re\u2010induce remissions with donor leucocytes provides additional benefit in favour of allogeneic HSCT.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2008.07067.x","type":"journal-article","created":{"date-parts":[[2008,3,4]],"date-time":"2008-03-04T00:06:12Z","timestamp":1204589172000},"page":"235-243","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Outcome of BEAM\u2010autologous and BEAM\u2010alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma"],"prefix":"10.1111","volume":"141","author":[{"given":"Wendy","family":"Ingram","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Devereux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma P.","family":"Das\u2010Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel H.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew P.","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bronwen E.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aloysius","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghulam J.","family":"Mufti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Pagliuca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,3,18]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.8.3257.3257"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700781"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1205"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.088"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03992.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4357"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0377"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_6_10_1","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood.V81.5.1137.1137","article-title":"The place of high\u2010dose BEAM therapy and autologous bone marrow transplantation in poor\u2010risk Hodgkin\u2019s disease. A single\u2010center eight\u2010year study of 155 patients","volume":"81","author":"Chopra R.","year":"1993","journal-title":"Blood"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01879.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3920"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1406"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.10.1470"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703898"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198412063112303"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704124"},{"key":"e_1_2_6_19_1","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood.V100.4.1141.h81602001141_1141_1152","article-title":"Intensive therapies in follicular non\u2010Hodgkin lymphomas","volume":"100","author":"Hunault\u2010Berger M.","year":"2002","journal-title":"Blood"},{"key":"e_1_2_6_20_1","volume-title":"Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissue","author":"Jaffe E.S.","year":"2001"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.1.140"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.3.649.649"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3595"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0982"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3257"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)60328-5"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704290"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03153.x"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.5.947"},{"key":"e_1_2_6_30_1","first-page":"253","article-title":"Autologous blood or bone marrow transplantation for relapsed and partially responding low\u2010grade non\u2010hodgkin\u2019s lymphoma","volume":"5","author":"Mijovic A.","year":"1998","journal-title":"Cancer Research Therapy and Control"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.588"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1105"},{"key":"e_1_2_6_33_1","volume-title":"Cancer Therapy Evaluation Programme, Common Toxicity Criteria Manual, Common Toxicity Criteria","author":"National Cancer Institute","year":"1999"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-6-200603210-00007"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0701"},{"key":"e_1_2_6_36_1","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka D.","year":"1995","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_6_37_1","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood.V84.4.1050.1050","article-title":"Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non\u2010Hodgkin\u2019s lymphoma","volume":"84","author":"Ratanatharathorn V.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1275"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.47.4.313"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.023"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2004"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2004.00360.x"},{"key":"e_1_2_6_43_1","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1182\/blood.V90.10.4201","article-title":"Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low\u2010grade non\u2010Hodgkin\u2019s lymphoma","volume":"90","author":"Verdonck L.F.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10924"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2008.07067.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2008.07067.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T01:40:43Z","timestamp":1697420443000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2008.07067.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,18]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1111\/j.1365-2141.2008.07067.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07067.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,18]]},"assertion":[{"value":"2008-03-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}